STATROL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
STATROL by Alcon is clinical pharmacology the anti-infective components in statrol ophthalmic ointment provide action against specific organisms susceptible to them. Approved for the topical treatment of infections of the external eye, its adnexa caused by susceptible bacteria. First approved in 1974.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STATROL is an ophthalmic small-molecule solution approved in 1974 for eye care indications. The specific mechanism of action and therapeutic class are not publicly documented in available records. This is a legacy product with established clinical use in ophthalmology.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; commercial team is likely in defensive/transition mode with limited growth investment.
Mechanism of Action
CLINICAL PHARMACOLOGY The anti-infective components in STATROL Ophthalmic Ointment provide action against specific organisms susceptible to them. Polymyxin B Sulfate and Neomycin Sulfate are active in vitro against Staphylococcus aureus, Escherichia coli, Klebsiella/Enterobacter species, Neisseria…
Worked on STATROL at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.